Anti‐TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta‐analysis-Reference-Cited by-同舟云学术

Anti‐TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta‐analysis

Published:2021-06-29 Issue:7 Volume:22 Page:408-418
ISSN:1751-2972
Container-title:Journal of Digestive Diseases
language:en
Short-container-title:J Dig Dis

Author:

Chen Liang¹²^ORCID,Xu Chun Jin¹,Wu Wei²,Ding Bai Jing³,Liu Zhan Ju²^ORCID

Affiliation:

1. Department of Gastroenterology The First People's Hospital of Shangqiu City, Xinxiang Medical University Shangqiu Henan Province China

2. Department of Gastroenterology Shanghai Tenth People's Hospital, Tongji University Shanghai China

3. Department of Gastroenterology Wuhu First People's Hospital Wuhu Anhui Province China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Gastroenterology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1751-2980.13026

Reference63 articles.

1. The changing pattern of Crohn’s disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007)

2. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

5. The Impact of Inflammatory Bowel Disease in Canada 2018: Quality of Life

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis;Digestive Diseases and Sciences;2024-06-14

2. Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn’s disease;Therapeutic Advances in Gastroenterology;2024-01

3. The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease;Annals of Gastroenterology;2021